Sonia Simoes, MD
Nephrology · Newark, NJNPI 1346406600
Payments from drug & device makers
Across 181 payments — averaging $18.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$553
- Vifor Pharma, Inc.$494
- Bayer$291
- Novo Nordisk$282
- Amgen$225
- Boehringer Ingelheim$175
- plus $1K from 17 others
What the payments were for
- Food & beverage$2,96791%
- Education$2969%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 30 | $553 |
| Vifor Pharma, Inc. | 33 | $494 |
| Bayer | 13 | $291 |
| Novo Nordisk | 13 | $282 |
| Amgen(2 entities) | 15 | $225 |
| Boehringer Ingelheim | 11 | $175 |
| Ardelyx, Inc. | 4 | $172 |
| Otsuka America Pharmaceutical, Inc. | 8 | $153 |
| Mallinckrodt Enterprises LLC | 6 | $132 |
| Mallinckrodt Hospital Products Inc. | 8 | $109 |
| Novartis | 6 | $101 |
| OPKO Pharmaceuticals, LLC | 7 | $93 |
| Merck | 6 | $90 |
| Aurinia Pharma U.S., Inc. | 5 | $74 |
| Outset Medical Inc | 1 | $72 |
| Lilly USA, LLC | 5 | $68 |
| Calliditas Therapeutics US Inc. | 2 | $43 |
| Akebia Therapeutics Inc | 2 | $42 |
| ANI Pharmaceuticals, Inc. | 2 | $36 |
| Baxter Healthcare | 1 | $18 |
| GSK | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$125
- XPHOZAH 30 MG$124
How this compares
$3,263 in reported general payments places this provider in the 70th percentile of 413 nephrology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 207 | $271,633 |
| LokelmaSodium Zirconium Cyclosilicate | 140 | $198,932 |
| VelphoroSucroferric Oxyhydroxide | 79 | $181,501 |
| Diclofenac Sodium | 97 | $174,710 |
| VeltassaPatiromer Calcium Sorbitex | 91 | $164,099 |
| XphozahTenapanor Hcl | 41 | $151,975 |
| JardianceEmpagliflozin | 116 | $151,513 |
| JanuviaSitagliptin Phosphate | 85 | $119,965 |
| ProcritEpoetin Alfa | 49 | $89,031 |
| OzempicSemaglutide | 34 | $65,037 |
| EliquisApixaban | 61 | $62,495 |
| MounjaroTirzepatide | 48 | $61,188 |
| TradjentaLinagliptin | 57 | $60,397 |
| TrulicityDulaglutide | 35 | $54,495 |
| LinzessLinaclotide | 61 | $52,731 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $553 | $470,565347 claims |
| Boehringer IngelheimJardiance, Tradjenta | $175 | $211,910173 claims |
| MerckJanuvia | $90 | $119,96585 claims |
| Lilly USA, LLCMounjaro, Trulicity | $68 | $115,68383 claims |
| Novo NordiskOzempic | $282 | $65,03734 claims |
| BayerKerendia | $291 | $30,28728 claims |
| AmgenEpogen | $225 | $14,82413 claims |
| GSKBreo Ellipta | $14 | $13,36129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 413 nephrology providers in New Jersey.
Other nephrology in Newark
- Joshua KaplanNewark$509K
- Danny HaddadJersey City$1.7M
- Anup PatelWest Orange$1M
- Lawrence ByrdLivingston$338K
- Devang LodhaviaVoorhees$321K
- Jeffrey FeldmanUnion$315K
- Kenneth LissEatontown$271K
- Narender GoelJersey City$181K
- Vadim FinkielsteinPrinceton Junction$139K
- Neeraj SinghNew Brunswick$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.